What is UBRELVY?
UBRELVY is a medication used to treat acute migraine headaches in adults. It is a type of medicine called a CGRP receptor antagonist, which means it blocks the binding of calcitonin gene-related peptide (CGRP) in the brain, a neuropeptide that plays a key role in the development of migraine headaches.
UBRELVY is taken as a tablet, and its effects develop quickly, making it an attractive treatment option for those who experience sudden and severe migraine attacks. It works by reducing the inflammation in the blood vessels in the brain, which are known to cause migraines.
In clinical trials, UBRELVY has been shown to be a highly effective treatment for acute migraines, with many patients experiencing significant relief from their symptoms within two hours of taking the medication. Common side effects of UBRELVY include nausea, fatigue, and dry mouth.
It is important to note that UBRELVY is not a preventive treatment for migraines, and should only be used to treat acute migraine attacks. It is also not recommended for individuals with severe liver or kidney disease or who have a history of heart disease.
If you suffer from migraines and are looking for an effective acute treatment, UBRELVY may be an option to discuss with your healthcare professional. As with any medication, it is important to understand the potential benefits and risks before you begin taking it.
Frequently Asked Questions about ubrelvy
It helps to relieve headache, pain, and other migraine symptoms (including nausea, vomiting, sensitivity to light/sound). Prompt treatment helps you return to your normal routine and may decrease your need for other pain medications.
Ubrelvy contains the active drug ubrogepant. It belongs to a group of drugs called oral calcitonin gene-related peptide (CGRP) antagonists. These drugs are more commonly known as gepants. Ubrelvy comes as a tablet that's taken by mouth when migraine symptoms start to occur.
Ubrelvy (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor blocker. High levels of CGRP cause pain and inflammation, which commonly leads to migraines. Ubrelvy (ubrogepant) blocks CGRP to prevent it from causing pain and inflammation, which leads to relief of migraines.
Ubrelvy belongs to a group of medications known as small molecule calcitonin gene-related peptide receptor antagonists or gepants. It is available in tablet form (50 and 100mg) and is taken orally.
Effectiveness for migraine
| 2 hours after taking Ubrelvy: | 2 hours after taking a placebo: |
|---|
| People who had migraine pain relief* | 60.7% to 62.7% | 48.2% to 49.1% |
| People who had no migraine pain | 19.2% to 21.8% | 11.8% to 14.3% |
| People who no longer had their most bothersome symptom†| 37.7% to 38.9% | 27.4% to 27.8% |
The FDA approved UBRELVY based on evidence from two clinical trials (Trial 1/NCT02828020 and Trial 2/NCT02867709) of 2423 patients with migraine headaches. Trials were conducted at 188 sites in the United States.
UBRELVY stops CGRP proteins from reaching the postsynaptic neurons, thereby blocking migraine pain signaling. UBRELVY works differently: UBRELVY stops CGRP proteins from reaching the postsynaptic neurons, thereby blocking migraine pain signaling.
Effectiveness for migraine
| 2 hours after taking Ubrelvy: | 2 hours after taking a placebo: |
|---|
| People who had migraine pain relief* | 60.7% to 62.7% | 48.2% to 49.1% |
| People who had no migraine pain | 19.2% to 21.8% | 11.8% to 14.3% |
| People who no longer had their most bothersome symptom†| 37.7% to 38.9% | 27.4% to 27.8% |
The FDA approved UBRELVY based on evidence from two clinical trials (Trial 1/NCT02828020 and Trial 2/NCT02867709) of 2423 patients with migraine headaches. Trials were conducted at 188 sites in the United States.
UBRELVY stops CGRP proteins from reaching the postsynaptic neurons, thereby blocking migraine pain signaling. Triptans are agonists that bind to presynaptic serotonin receptors (5-HT1B or 5-HT1D), constricting blood vessels and preventing release of additional neuropeptides, including CGRP.
UBRELVY LIST PRICE. The Wholesale Acquisition Cost (WAC), also known as the list price for one dose of UBRELVY is $98.40, or $983.99 per month, as of January 2023. The WAC may not reflect the price paid by patients. Call 1 (800) 678-1605 (option 4) to find out how much UBRELVY will cost for you.
Nausea. Nausea was the most common side effect reported by people taking Ubrelvy in clinical trials. Nausea is also a possible symptom of migraine episodes. You may be slightly more likely to have nausea from taking the 100-mg dose of Ubrelvy compared with the 50-mg dose.
